Olema Pharmaceuticals (OLMA) late Tuesday reported Q4 net loss of $0.51 per diluted share, compared with $0.49 loss a year earlier.
The four analysts polled by FactSet, on average, expected a loss of $0.65.
The biopharmaceutical company recorded no revenue during the quarter ended Dec. 31, as expected.
Olema finished 2024 with around $434.1 million in cash and equivalents, up from $261.8 million at the end of 2023.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。